| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
EDAP TMS S.A. American Depositary Shares$4.98
+0.08 (+1.63%)
Market Cap
-
EPS
-
P/E Ratio
-
Value Trade
-
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
70.22 K
52 Week Range
-
% held by Insiders
0.53 %
% held by Institutions
38.86 %
Enterprise Value
-
Total Shares
-
Short %
0.15 %
Float Shares
-
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in FOCL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
EDAP TMS S.A. American Depositary Shares (FOCL) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
FOCL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
FOCL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
FOCL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
FOCL Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
FOCL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-FOCL
Jun 1, 20262026 Investor Day Nasdaq (FOCL) June 1, 2026 1
FocalTherics is gearing up for its 2026 Investor Day, highlighting its strategic transformation into a leader in robotic focal therapy. The company aims to focus on High Intensity Focused Ultrasound (HIFU) technology, especially in treating prostate cancer, while planning to discontinue its Extracorporeal Shock Wave Lithotripsy (ESWL) operations. Management projects strong revenue growth as they expand their market presence and emphasize innovative approaches in therapeutics. However, they acknowledge various risks associated with market acceptance, competition, and the transition away from non-core segments.
Read more →-FOCL
Mar 18, 2026The Global Leader in Therapeutic Ultrasound 1
Focal One is positioned as a global leader in therapeutic ultrasound, particularly in treating prostate cancer. The technology utilizes high-intensity focused ultrasound (HIFU) for optimal cancer control while preserving quality of life. With approximately 1.5 million new prostate cancer cases each year, the technology meets an urgent need in a large and underserved patient population. Positive clinical outcomes demonstrate the efficacy of HIFU compared to traditional surgical options, suggesting a paradigm shift in prostate cancer management.
Read more →-FOCL
Jan 12, 2026EDAP Announces Preliminary Record Fourth Quarter and
EDAP TMS SA announced record revenues for the fourth quarter and full year 2025, primarily from its HIFU business. The company reported a 69% increase in Focal One system placements and a 28% growth in procedures in the U.S., highlighting strong global demand. With preliminary revenue guidance for 2026 indicating continued growth, EDAP's CEO emphasized the increasing clinical validation supporting the adoption of their prostate cancer treatments. The company expects significant revenue contributions from its core and non-core businesses in the upcoming year.
Read more →-FOCL
Sep 9, 2025SECURITIES AND EXCHANGE COMMISSION
The report highlights the strong market potential of Focal One's Robotic HIFU therapy for prostate cancer, indicating its ability to address significant unmet clinical needs. With proven clinical evidence and a growing worldwide install base, the technology is positioned to transform prostate cancer treatment paradigms. The report emphasizes increasing patient and physician demand, alongside strong reimbursement support from hospitals. Overall, Focal One's focus on advanced imaging and robotic techniques represents a promising future in urological therapies.
Read more →Competitive Position
How FOCL ranks across every disease it competes inCompetitive Position is a premium feature
See how FOCL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial